Cullinan Therapeutics Inc (NASDAQ: CGEM) started the day on Wednesday, with a price decrease of -6.27% at $10.77, before settling in for the price of $11.49 at the close. Taking a more long-term approach, CGEM posted a 52-week range of $8.02-$30.19.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -20.00%. Meanwhile, its Annual Earning per share during the time was -62.42%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 17.66%. This publicly-traded company’s shares outstanding now amounts to $58.14 million, simultaneously with a float of $37.15 million. The organization now has a market capitalization sitting at $627.12 million. At the time of writing, stock’s 50-day Moving Average stood at $14.52, while the 200-day Moving Average is $17.91.
Cullinan Therapeutics Inc (CGEM) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Cullinan Therapeutics Inc’s current insider ownership accounts for 36.20%, in contrast to 77.32% institutional ownership. According to the most recent insider trade that took place on Dec 12 ’24, this organization’s Chief Scientific Officer sold 3,489 shares at the rate of 12.52, making the entire transaction reach 43,682 in total value, affecting insider ownership by 104,453. Preceding that transaction, on Nov 05 ’24, Company’s Chief Scientific Officer sold 8,000 for 15.64, making the whole transaction’s value amount to 125,120. This particular insider is now the holder of 107,942 in total.
Cullinan Therapeutics Inc (CGEM) Earnings and Revenue Records
Cullinan Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 17.66% and is forecasted to reach -3.17 in the upcoming year.
Cullinan Therapeutics Inc (NASDAQ: CGEM) Trading Performance Indicators
Let’s observe the current performance indicators for Cullinan Therapeutics Inc (CGEM). It’s Quick Ratio in the last reported quarter now stands at 24.46. The Stock has managed to achieve an average true range (ATR) of 0.76.
In the same vein, CGEM’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.88, a figure that is expected to reach -0.79 in the next quarter, and analysts are predicting that it will be -3.17 at the market close of one year from today.
Technical Analysis of Cullinan Therapeutics Inc (CGEM)
If we take a close look at the recent performances of Cullinan Therapeutics Inc (NASDAQ: CGEM), its last 5-days Average volume was 0.45 million that shows plunge from its year to date volume of 0.64 million. During the previous 9 days, stock’s Stochastic %D was recorded 10.29% While, its Average True Range was 0.72.
Raw Stochastic average of Cullinan Therapeutics Inc (CGEM) in the period of the previous 100 days is set at 2.88%, which indicates a major fall in contrast to 8.23% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 44.42% that was lower than 53.82% volatility it exhibited in the past 100-days period.
